The INFECIR-2 Albumin Prevention Study

Summary

The aim of this study is to evaluate whether albumin administration improves short-term survival in patients with advanced cirrhosis and bacterial infections other than Spontaneous Bacterial Peritonitis (SBP).

Conditions

• Advanced Chronic Liver Disease
• Urinary Infection
• Pneumonia
• Cholangitis
• Other Bacterial Diseases

Interventions

DRUG

Albumin

Intravenous infusion of 20% albumin

Sponsors & Collaborators

• EASL - CLIF Consortium

  lead OTHER

Principal Investigators

• Thierry Gustot · Erasme University Hospital, Brussels, Belgium

• Frederick Nevens · University Hospitals KU, Leuven, Belgium

• Faouzi Saliba · Hôpital Paul Brousse, Villejuif, France

• François Durand · Hôpital Beaujon, Clichy, France

• Matthias Dollinger · University of Ulm, Heidelberg and Tübingen, Germany

• Stefan Zeuzem · University Hospital of Frankfurt, Germany

• Alexander Gerbes · University Hospital of Munich, Germany

• Jonel Trebicka · University Hospital of Bonn, Germany

• Henning Gronbaeck · Aarhus University Hospital

• Fin Stolze Larsen · Rigshospitalet, University of Copenhagen

• John Willy Haukeland · Oslo University Hospital

• Andrea de Gottardi · Bern University Hospital, Switzerland

• Aide McCormick · University College of Dublin, Ireland

• Rajiv Jalan · University College, London

• Marco Domenicali · Santa Orsola-Malpighi Hospital, Bologna, Italy

• Paolo Angeli · University of Padova, Italy

• Carlo Alessandria · San Giovanni Battista Hospital, University of Turin, Italy

• Francesco Salerno · Policlinico IRCCS San Donato, University of Milan, Italy

• Agustin Albillos · Hospital Ramon y Cajal, Madrid, Spain

• Victor Vargas · Hospital Vall d'Hebron, Barcelona, Spain

• Javier Fernandez · Hospital Clinic, Barcelona, Spain

• German Soriano · Hospital Santa Creu i Sant Pau, Barcelona, Spain

• Rafael Bañares · Hospital Gregorio Marañon, Madrid, Spain

• Jose Luis Montero · Hospital Reina Sofia, Cordoba, Spain

• Manuela Merli · Sapienza University of Rome, Italy

• Minneke Coenraad · Leiden University Medical Center

• Rudolf Stauber · Medical University of Graz

• Wolfgang Vogel · Medical Hospital Innsbrück

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-05-31

Primary Completion

2016-12-31

Completion

2017-02-10

Countries

• Spain

Study Locations